Lowest Price Guaranteed From USD 5,899
Published
August 2021
Pages
131
View Count
3722
-thumb.PNG) |
 |
-thumb.PNG) |
 |
-thumb.PNG) |
-thumb.PNG) |
-thumb.PNG) |
-thumb.PNG) |
-thumb.PNG) |
-thumb.PNG) |
 |
-thumb.PNG) |
Close to 10 million fatalities reported in 2020 were observed to be associated with cancer, which is believed to be one of the leading causes of death, globally. One of the primary reasons for the high mortality rate associated with this condition is anticipated to be late diagnosis, which eventually results in delayed treatment, further leading to severe compromises with chances of survival of a patient. Moreover, post the onset of the COVID-19 pandemic, the treatment of cancer patients has become arduous, as patient visits are being cancelled by healthcare facilities in order to preserve resources and prevent patients from getting infected with SARS-CoV-2. Further, as per the National Cancer Institute, the delay in screening and treatment of cancer patients due to the COVID-19 pandemic is likely to result in 10,000 deaths, which could have been otherwise prevented, over the next decade. Specifically, in 2020, the global prevalence of human cancers was estimated to be 50.5 million; of this, majority of the cases were reported to be of breast cancer and lung cancer. Since a large share of the population remains affected with various oncological indications, cancer therapeutics continue to be one of the most active segments, in terms of drug development efforts, within the pharmaceutical industry.
Given the complexities associated with conventional cancer treatment options, such as chemotherapy and radiation therapy, drug developers engaged in this domain have shifted their focus on the development of drugs against specific oncogenic mutations that are primarily responsible for the disease development and / or progression. It is worth mentioning that one such target (RAS), which was previously considered undruggable, was found to be associated with 30% of cancers in humans. Over the years, several drug candidates have been evaluated to target specific RAS mutated genes. In 2021, LUMAKRAS™ (sotorasib), a RAS targeting small molecule was approved by the USFDA for the treatment of metastatic non-small cell lung cancer in patients with KRAS G12C mutations. Given its high efficacy and good safety profile, significant efforts are being made to evaluate the potential of the aforementioned drug across multiple solid tumor indications, such as colorectal cancer. Presently, several companies (including big pharma players), independently or in collaboration with other stakeholders, are actively engaged in the development of RAS targeting therapies. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. As more candidates are likely to progress towards advanced stages of development, we expect the market to witness aggressive growth in the foreseen future.
The ‘RAS Targeting Therapies by Target Indication (Acute Myeloid Leukemia, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Phelan-McDermid Syndrome, and Skin Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy and Combination Therapy), and Route of Administration (Intravenous, Intramuscular, Intradermal, Intraocular, Intraperitoneal, Oral, and Subcutaneous), Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2031, report features an extensive study of the current landscape, offering an informed opinion on the likely evolution of this industry, over the next decade. Further, the study underlines an in-depth analysis of players engaged in the development of RAS targeting therapies. Amongst other elements, the report features:
One of the key objectives of the report was to estimate the existing market size and future growth potential associated with RAS targeting therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption rates and likely annual treatment cost of RAS targeting therapies, we have developed informed estimates on the evolution of the market over the coming decade. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] target indication (acute myeloid leukemia, colorectal cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, Phelan-Mcdermid syndrome and skin cancer), [B] type of molecule (biologic and small molecule), [C] type of therapy (monotherapy, combination therapy), [D] route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral, and subcutaneous), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the RAS targeting therapies market and its likely evolution in the short to mid term and long term.
Chapter 3 provides a general introduction to various aspects of mutated RAS genes. In addition, it includes information on the role of RAS targeting therapies in the treatment of cancer, including details on the RAS gene mutations and the type of molecules that are being developed. Further, it highlights various challenges associated with the use of RAS targeting therapies and its future perspectives.
Chapter 4 provides an overview of more than 85 molecules that are currently under development for the treatment of various cancer indications, along with a detailed analysis of these molecules, based on current status of development (marketed, clinical, pre-clinical and discovery), phase of development (phase III, phase II, phase I / II and phase I), type of molecule (biologic and small molecule), type of therapy (monotherapy and combination therapy), target therapeutic area (blood cancer, colorectal cancer, esophageal cancer, head and neck cancer, lung cancer, pancreatic cancer, skin cancer, and undisclosed solid tumors), target gene (HRAS, KRAS and NRAS), line of treatment and route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral and subcutaneous), In addition, it presents details of companies engaged in the development of RAS targeting therapies, based on several relevant parameters, such as year of establishment, employee count, and geographical presence.
Chapter 5 provides a detailed analysis of more than 120 completed, ongoing and planned clinical studies of RAS targeting therapies, based on several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target indication, most popular indications and regional distribution of trials.
Chapter 6 features an insightful competitive analysis, highlighting the key players engaged in this domain (on the basis of the strength of their respective development portfolios), along with information on several relevant parameters, such as company size and stage of development of lead molecules.
Chapter 7 includes detailed profiles of the key players (shortlisted based on number of pipeline products) engaged in offering RAS targeting therapies. Each profile includes a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook.
Chapter 8 provides a detailed review of close to 1,600 peer-reviewed, scientific articles related to research on RAS targeting therapies, which have been published between January 2020 and April 2021. It also discusses the trends across year of publication, focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in this domain and impact factor of the journal).
Chapter 9 features a detailed analysis of recent partnerships inked between various stakeholders engaged in this domain, during the period 2016-2021. Additionally, it includes a brief description of the various types of partnership models (such as R&D agreements, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements) that have been adopted by stakeholders engaged in this domain, during the period 2016-2021.
Chapter 10 provides a detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by companies engaged in this domain, during the period 2016-2021.
Chapter 11 features an elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in this domain across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing stage.
Chapter 12 presents an insightful market forecast analysis, highlighting the future potential of RAS targeting therapies, till 2030. We have segmented the market on the basis of [A] target indication (acute myeloid leukemia, colorectal cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, Phelan-Mcdermid syndrome and skin cancer), [B] type of molecule (biologic and small molecule), [C] type of therapy (monotherapy and combination therapy), [D] route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral, and subcutaneous), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).
Chapter 13 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of RAS Targeting Therapies
3.2. Approaches Used to Target Mutated RAS Gene
3.3. Historical Notable Developments
3.4. Prominent Gene Driver Related Mutations in RAS Mutated Cancers
3.5. Challenges and Future Perspectives Associated with Treatment of RAS Mutated Cancers
4. CURRENT MARKET LANDSCAPE
4.1. RAS Targeting Therapies: Pipeline Review
4.1.1. Analysis by Phase of Development
4.1.2. Analysis by Route of Administration
4.1.3. Analysis by Line of Treatment
4.1.4. Analysis by Type of Therapy
4.1.5. Analysis by Type of Molecule
4.1.6. Analysis by Target Gene
4.1.7. Analysis by Target Therapeutic Area
4.1.8. Analysis by Phase of Development and Leading Players
4.2. RAS Targeting Therapies: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Geography
5. CLINICAL TRIALS AND ENDPOINT ANALYSIS
5.1. RAS Targeting Therapies: List of Clinical Trials
5.1.1. Analysis by Trial Status
5.1.2. Analysis by Trial Registration Year
5.1.3. Analysis by Type of Masking
5.1.4. Analysis by Type of Intervention Model
5.1.5. Analysis by Study Design
5.1.6. Analysis by Type of Sponsor
5.1.7. Most Active Players: Analysis by Number of Trials Registered
5.1.8. Analysis by Trial Registration Year and Geography
5.1.9. Analysis by Type of Target Indication
5.1.10. Analysis by Enrolled Patient Population
5.1.11. Analysis of Enrolled Patient Population by Geography
5.1.12. Analysis of Number of Clinical Trials by Geography
6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Product Competitiveness: North America
6.2. Product Competitiveness: Europe
6.3. Product Competitiveness: Asia-Pacific
7. COMPANY PROFILES
7.1. Amgen
7.1.1. Company Overview
7.1.2. Financial Information
7.1.3. Portfolio of RAS Targeting Therapies
7.1.4. Recent Developments and Future Outlook
7.2. GlobeImmune
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Portfolio of RAS Targeting Therapies
7.2.4. Recent Developments and Future Outlook
7.3. Jacobio Pharmaceuticals
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Portfolio of RAS Targeting Therapies
7.3.4. Recent Developments and Future Outlook
7.4. Mirati Therapeutics
7.4.1. Company Overview
7.4.2. Financial Information
7.4.3. Portfolio of RAS Targeting Therapies
7.4.4. Recent Developments and Future Outlook
7.5. Novartis
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Portfolio of RAS Targeting Therapies
7.5.4. Recent Developments and Future Outlook
7.6. Onconova Therapeutics
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. Portfolio of RAS Targeting Therapies
7.6.4. Recent Developments and Future Outlook
7.7. Targovax
7.7.1. Company Overview
7.7.2. Financial Information
7.7.3. Portfolio of RAS Targeting Therapies
7.7.4. Recent Developments and Future Outlook
7.8. Verastem Oncology
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. Portfolio of RAS Targeting Therapies
7.8.4. Recent Developments and Future Outlook
8. PUBLICATION ANALYSIS
8.1. RAS Targeting Therapies: Recent Publications
8.1.1. Analysis by Year of Publication
8.1.2. Analysis by Type of Publication
8.1.3. Analysis by Study Objective
8.1.4. Analysis by Emerging Focus Areas
8.1.5. Analysis by Target Therapeutic Area
8.1.6. Analysis by Target Gene
8.1.7. Analysis by Target Indication
8.1.8. Analysis by Affiliation of First Author
8.1.9. Leading Players: Analysis by Number of Publications
8.1.10. Key Journals: Analysis by Number of Publications
9. PARTNERHSIPS AND COLLABORATIONS
9.1. RAS Targeting Therapies: List of Partnerships and Collaborations
9.1.1. Analysis by Year of Partnership
9.1.2. Analysis by Type of Partnership
9.1.3. Analysis by Type of Partner
9.1.4. Analysis by Type of Molecule
9.1.5. Most Active Players: Analysis by Number of Partnerships
9.1.6. Most Active Partners: Analysis by Number of Partnerships
9.1.7. Regional Analysis
9.1.8. Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. RAS Targeting Therapies: Funding and Investments
10.1.1. Analysis by Number of Funding Instances
10.1.2. Analysis by Amount Invested
10.1.3. Analysis by Type of Funding
10.1.4. Most Active Players: Analysis by Amount Raised
10.1.5. Most Active Investors: Analysis by Number of Instances
10.1.6. Analysis by Geography
11. KEY COMMERCIALIZATION STRATEGIES
11.1. Successful Drug Launch Strategy: ROOTS Framework
11.2. Successful Drug Launch Strategy: Product Differentiation
11.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
11.4. Key Commercialization Strategies Adopted by Companies Focused on RAS Targeting Therapies
11.4.1. Strategies Adopted Before Therapy Approval
11.5. Strategies Adopted During / Post Therapy Approval
11.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)
12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Forecast Methodology and Key Assumptions
12.2. Global RAS Targeting Therapies Market, 2021-2031
12.3. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Target Indication
12.4. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Type of Molecule
12.5. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Type of Therapy
12.6. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Route of Administration
12.7. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Geography
12.8. RAS Targeting Therapies: Individual Product Sales Forecasts
12.8.1. LUMAKRASTM (Amgen): Sales Forecast
12.8.2. Adagrasib (Mirati Therapeutics): Sales Forecast
12.8.3. AMO-01 (AMO Pharma): Sales Forecast
12.8.4. Antroquinonol (Golden Biotech): Sales Forecast
12.8.5. Binimetinib (Array Biopharma): Sales Forecast
12.8.6. CH7126766/VS6766 (Verastem Oncology): Sales Forecast
12.8.7. LXH274 (Novartis): Sales Forecast
12.8.8. Rigosertib (Onconova Therapeutics): Sales Forecast
12.8.9. RMC-4630 (Revolution Medicine): Sales Forecast
12.8.10. TG01 (Targovax): Sales Forecast
12.8.11. Tipifarnib (Kura Oncology): Sales Forecast
12.8.12. siG12D (Silenseed): Sales Forecast
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Approaches for Targeting Mutated RAS Gene
Figure 3.2 Notable Developments within the RAS Targeting Therapies Domain
Figure 3.3 Prominent Gene Driver related Mutations in RAS Mutated Cancers
Figure 3.4 Key Challenges Associated with Targeting and Treatment of RAS Mutated Cancers
Figure 3.5 Future Perspectives of RAS Targeting Therapies
Figure 4.1 RAS Targeting Therapies: Distribution by Phase of Development
Figure 4.2 RAS Targeting Therapies: Distribution by Route of Administration
Figure 4.3 RAS Targeting Therapies: Distribution by Line of Treatment and Type of Therapy
Figure 4.4 RAS Targeting Therapies: Distribution by Type of Molecule
Figure 4.5 RAS Targeting Therapies: Distribution by Phase of Development and Type of Molecule
Figure 4.6 RAS Targeting Therapies: Distribution by Type of Molecule and Route of Administration
Figure 4.7 RAS Targeting Therapies: Distribution by Target Gene and Target Indication
Figure 4.8 Most Active Players: Distribution by Number of Trials Registered
Figure 4.9 RAS Targeting Therapy Developers: Distribution by Year of Establishment
Figure 4.10 RAS Targeting Therapy Developers: Distribution by Company Size
Figure 4.11 RAS Targeting Therapy Developers: Distribution by Location of Headquarters
Figure 4.12 RAS Targeting Therapy Developers: Distribution by Geography
Figure 5.1 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
Figure 5.2 Clinical Trial Analysis: Distribution by Type of Masking and Intervention Model Adopted
Figure 5.3 Clinical Trial Analysis: Distribution by Study Design and Trial Status
Figure 5.4 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 5.5 Most Active Players: Distribution by Number of Clinical Trials
Figure 5.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 5.7 Clinical Trial Analysis: Distribution by Target Indication
Figure 5.8 Clinical Trial Analysis: Distribution of Number of Trials by Geography
Figure 5.9 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patients Population
Figure 5.10 Clinical Trial Analysis: Distribution by Geography, Patients Enrolled and Trial Status
Figure 5.11 Clinical Trial Analysis: Distribution by Patients Enrolled and Phase of Development
Figure 6.1 Product Competitiveness Analysis: North America Scenario
Figure 6.2 Product Competitiveness Analysis: Europe Scenario
Figure 6.3 Product Competitiveness Analysis: Asia-Pacific Scenario
Figure 7.1 Amgen: Financial Information
Figure 7.2 GlobeImmune: Financial Information
Figure 7.3 Jacobio Pharmaceuticals: Financial Information
Figure 7.4 Mirati Therapeutics: Financial Information
Figure 7.5 Novartis: Financial Information
Figure 7.6 Onconova Therapeutics: Financial Information
Figure 7.7 Targovax: Financial Information
Figure 7.8 Verastem Oncology: Financial Information
Figure 8.1 Publication Analysis: Distribution by Year of Publication
Figure 8.2 Publication Analysis: Distribution by Type of Publication
Figure 8.3 Publication Analysis: Distribution by Study Objective
Figure 8.4 Publication Analysis: Distribution by Emerging Focus Area
Figure 8.5 Publication Analysis: Distribution by Target Gene
Figure 8.6 Publication Analysis: Distribution by Target Therapeutic Area
Figure 8.7 Publication Analysis: Distribution by Target Indication
Figure 8.8 Publication Analysis: Distribution by Affiliation of First Author
Figure 8.9 Most Active Players: Distribution by Number of Publications
Figure 8.10 Key Journals: Distribution by Number of Publications
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 9.5 Most Active Players: Distribution by Number of Partnerships
Figure 9.6 Most Active Partners: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Funding and Investment Analysis: Cumulative Year-wise Distribution by Amount Invested, 2016-2021
Figure 10.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 10.3 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 10.4 Funding and Investment Analysis: Distribution by Year, Amount Invested and Type of Funding, 2016-2021 (USD Million)
Figure 10.5 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 10.6 Key Investors: Distribution by Number of Funding Instances
Figure 10.7 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Figure 11.1 Key Commercialization Strategies: Harvey Ball Analysis
Figure 11.2 Successful Drug Launch Strategy: ROOTS Framework
Figure 11.3 Historical Strategies Adopted by the Developer of LUMAKRAS™
Figure 11.4 Successful Drug Launch Strategy: Product Differentiation
Figure 11.5 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 11.6 Harvey Ball Analysis: Commercialization Strategies Adopted by RAS Targeting Therapy Developers
Figure 12.1 RAS Targeting Therapies Market, 2021-2031 (USD Million)
Figure 12.2 RAS Targeting Therapies Market: Distribution by Type of Molecule / Drug Class (USD Million)
Figure 12.3 RAS Targeting Therapies Market: Distribution by Type of Therapy (USD Million)
Figure 12.4 RAS Targeting Therapies Market: Distribution by Route of Administration (USD Million)
Figure 12.5 RAS Targeting Therapies Market: Distribution by Location of Headquarters (USD Million)
Figure 12.6 LUMAKRAS™ (Amgen): Estimated Sales, 2021-2030 (USD Million)
Figure 12.7 Adagrasib (Mirati Therapeutics): Estimated Sales, 2021-2030 (USD Million)
Figure 12.8 AMO-01 (AMO Pharma): Estimated Sales, 2021-2030 (USD Million)
Figure 12.9 Antroquinonol (Golden Biotech): Estimated Sales, 2021-2030 (USD Million)
Figure 12.10 Binimetinib (Array Biopharma): Estimated Sales, 2021-2030 (USD Million)
Figure 12.11 CH7126766/VS6766 (Verastem Oncology): Estimated Sales, 2021-2030 (USD Million)
Figure 12.12 LXH274 (Novartis): Estimated Sales, 2021-2030 (USD Million)
Figure 12.13 Rigosertib (Onconova Therapeutics): Estimated Sales, 2021-2030 (USD Million)
Figure 12.14 RMC-4630 (Revolution Medicine): Estimated Sales, 2021-2030 (USD Million)
Figure 12.15 TG01 (Targovax): Estimated Sales, 2021-2030 (USD Million)
Figure 12.16 Tipifarnib (Kura Oncology): Estimated Sales, 2021-2030 (USD Million)
Figure 12.17 siG12D (Silenseed): Estimated Sales, 2021-2030 (USD Million)
Figure 13.1 RAS Targeting Therapies: Distribution by Target Therapeutic Area
Figure 13.2 RAS Targeting Therapies: Distribution by Type of Molecule and Company Size
Figure 13.3 RAS Targeting Therapies: Distribution by Company Size and Region
Figure 13.4 Most Active Players: Distribution by Number of Products
Figure 13.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 13.6 Clinical Trial Analysis: Distribution by Phase of Development, Year and Number of Patients
Figure 13.7 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Region
Figure 13.8 Clinical Trial Analysis: Distribution by Primary Purpose
Figure 13.9 Funding and Investment Analysis: Cumulative Number of Funding Instances by Year, 2016-2021
Figure 13.10 Funding and Investment Analysis: Cumulative Amount Invested, 2016-2021 (USD Million)
Figure 13.11 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, 2016-2021
Figure 13.12 Funding and Investment Analysis: Distribution of Funding Instances by Geography
Figure 13.13 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, 2016-2021
Figure 13.14 Most Active Players: Distribution by Number of Funding Instances, 2016-2021
Figure 13.15 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2016-2021
Table 4.1 RAS Targeting Therapies: List of Industry and Non-Industry Players
Table 5.1 RAS Targeting Therapies: List of Clinical Trials
Table 8.1 RAS Targeting Therapies: List of Recent Publications
Table 9.1 RAS Targeting Therapies: List of Partnerships and Collaborations
Table 10.1 RAS Targeting Therapies: List of Funding and Investments
The following companies and organizations have been mentioned in the report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES